deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02323113

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Sponsor: Calithera Biosciences, Inc

Conditions Acute Myelogenous Leukemia
Interventions TAK-659
Updated 16 times since 2017 Last updated: Feb 6, 2023 Started: Mar 9, 2015 Primary completion: Jun 8, 2018 Completion: Aug 15, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business Decision; No Safety or Efficacy Concerns.

Other terminated trials from Calithera Biosciences, Inc

More terminations from Calithera Biosciences, Inc

This PHASE1/PHASE2 trial investigates Acute Myelogenous Leukemia and is currently terminated or withdrawn. Calithera Biosciences, Inc leads this study, which shows 16 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Mar 2023 · 21 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Mar 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jun 2021 — Mar 2023 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  5. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jul 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Apr 2019 — Jul 2019 [monthly]

    Completed PHASE1_PHASE2

  3. Feb 2019 — Apr 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  4. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  7. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

  8. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  9. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE1

  10. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Calithera Biosciences, Inc
Data source: Calithera Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Chapel Hill, United States , Chicago, United States , Cincinnati, United States , Dallas, United States , Detroit, United States , Halifax, Canada and 5 more locations